England’s High Court has ruled it is lawful to use Roche’s Avastin (bevacizumab) in an unlicensed use in wet age-related macular degeneration (AMD) instead of more expensive approved drugs ...

Outlook Therapeutics’ eye disease drug has failed to match Roche’s Lucentis in a key trial. The biotech brushed off the ...

The FDA issued a “study may proceed” letter for the planned Phase III trial of 600mg BID amezalpat + Tecentriq+Avastin vs. Tecentriq+Avastin in 1st-line hepatocellular carcinoma. Tempest anticipates ...

The UK drugs regulator has endorsed the use of Roche’s Avastin as a treatment for age-related macular degeneration, a leading cause of blindness, even though it isn’t approved for that use.

marketed as Tecentriq and Avastin by Roche (OTCQX:RHHBY) (OTCQX:RHHBF). The global Phase 1b/2 study tested amezalpat in combination with atezolizumab and bevacizumab against the standard of care ...

Twelve NHS bodies in the north east of England were offering these patients Avastin, a cheaper alternative to the licensed drug, Lucentis. David Hambleton, chief executive officer of NHS South ...

The Mumbai-based chemical generics manufacturer is taking aim at top-selling biologics—Roche's Avastin (bevacizumab) and Herceptin (trastuzumab) and Pfizer/Amgen's Enbrel (etanercept)—which ...

At the same time, competitor Avastin (bevacizumab, Roche AG) has had trouble lately with supply disruptions of compounded Avastin which, some argue could favor branded VEGF products in the space.